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Abstract 
Non-inferiority trials have been widely used in many medical areas.  The goal of a non-
inferiority trial is to show that a new test therapy is either better or not too much worse than the 
active control rather than showing the test therapy is superior to a negative control (i.e. placebo).  
The appeal of a non-inferiority trial is that it is often unethical to give some patients a treatment 
with no therapeutic benefit.  When designing a non-inferiority trial, the issues of assay 
sensitivity, sample size, constancy condition, and a suitable non-inferiority margin need to be 
considered.  A poor choice of the non-inferiority margin is a major reason that many non-
inferiority trials fail.  A numerical example is presented to show how to estimate the non-
inferiority margin without historical data.
 Keywords:  non-inferiority trial, non-inferiority margin, superiority margin 
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Chapter 1 - What is a Non-inferiority Trial? 
 Introduction 
In recent years, testing for non-inferiority has become one of the hottest topics in the area 
of clinical trials.  There was only one non-inferiority trial published between 1989 and 1998.  In 
contrast, there were 582 published non-inferiority trials between 2000 and 2009 (Hurley, 
McKibbin, Moroney, & Suda, 2011).  Among the 43 new drug applications approved by the 
FDA between 2002 and 2009, two thirds of them provided a statistical analysis with tests for 
non-inferiority (Hurley et al., 2011).  Non-inferiority trials have been widely used to test drugs 
and vaccines used to treat or prevent many serious and life-threatening medical conditions such 
as blood clots, cancer, heart and kidney failure as well as infections and infectious diseases 
(Rothmann, Wiens, & Chan, 2012). 
Before talking about the issues and statistical explanations of non-inferiority trials, we 
would like to introduce how the idea of non-inferiority generated.  When we discuss the 
hypothesis tests, the most common one will be a superiority test which is the easiest way to 
evaluate the effect of a test treatment compared to a control treatment in clinical trial.  The 
control treatment can be a placebo control, which has no medical benefit, or an active control, 
which is a tested therapy.  In general, the purpose of the superiority test is to test whether the 
treatment is better than the control treatment.  Let 𝑀1 > 0 represent the smallest benefit of the 
treatment over a placebo control that is acceptable.  When researchers compare a new treatment 
to a placebo control or an active control, they try to make a statement based on the result of the 
data analysis.  Shortly speaking, the statement ‘superiority’ means that the test treatment is better 
than the control.  In statistics, we would say that ‘superiority’ means that the data analysis tells 
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us to reject the null hypothesis that the distributions of the treatment and the placebo (or the 
active control) are same (Schumi & Wittes, 2011). 
Now, let us use a figure (Figure 1.1) to explain the relationship among the superiority 
margin, confidence interval, and the idea of superiority.  Suppose we have treatments A and B, 
and we are testing whether treatment A is superior to treatment B.  If the confidence interval of 
the treatment difference is on the right side of superiority margin 𝑀1, then we can claim that 
treatment A is superior to treatment B.  Otherwise, we cannot state that treatment A is superior to 
treatment B. 
Another common statistical test is the equivalence test.  Instead of testing whether the test 
treatment is better than the control treatment, an equivalence test tries to determine whether the 
effect of the test treatment is the same as the control treatment for practical purposes.  Shortly 
speaking, ‘equivalence’ means the absolute difference between the treatment and the control is 
smaller than a fixed margin (Schumi & Wittes, 2011). 
 Now, let us use another figure (Figure 1.2) to explain the relationship among equivalence 
margin, confidence interval, and the idea of equivalence.  Suppose we have treatments A and B, 
and we are testing whether treatment A and treatment B are equivalent to each other.  If the 
confidence interval for the treatment difference is between −𝑀3 and 𝑀3 (with 𝑀3 > 0), then we 
can say that treatment A is equivalent to treatment B.  Otherwise, we cannot state that treatment 
A is equivalent to treatment B. 
Now, suppose we have to test a new treatment. Superiority testing, which in this case 
compares the new treatment to a placebo treatment, will be considered to be unethical, especially 
for testing drugs used to treat some medical conditions, such as cancer or sepsis, that are known 
to result in serious harm or death to patients receiving the placebo treatment.  Instead of using a 
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placebo as the control, a drug that has already been shown to be superior to a placebo, an active 
control, is used to judge the efficacy of the test drug.  If the new treatment is not superior to the 
active control, we cannot make conclusion that the new treatment has no medical benefit.  Then 
we use equivalence test to examine between the new treatment and the active control.  If it turns 
out that they are not equivalent, we still cannot state that the new treatment has no medical 
benefit.  The new treatment may be slightly less effective, but it may be a benefit to patients.  
Then we need a new hypothesis test to compare the new treatment to the active control. This is 
the idea that leads to a non-inferiority test.   
Even though ethical purposes could be the most important reason for non-inferiority 
trials, there are several situations when researchers may consider not performing a non-
inferiority trial according to Freedman (1987). 
1. Researchers should not try to perform a non-inferiority trial, when there is new 
evidence implies that there is uncertain side effect in the standard treatment or active 
control. 
2. There is no standard therapy can deal with some kind of disease.  In other words, we 
cannot find an active control agent. 
3. The effect of standard therapy is not significant. 
Now, let’s introduce the definition of non-inferiority trials.  If the effect of a new 
treatment is either better than or not too much worse than the effect of a proven treatment for a 
certain disease, the new treatment’s effect is said to be non-inferior to the effect of the proven 
treatment.  It is common to say that the new treatment is non-inferior to the proven treatment. 
Let us use figure (Figure 1.3) to explain the relationship among non-inferiority margin, 
confidence interval, and the idea of non-inferiority.  Suppose we have treatments A and B, and 
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we are testing whether treatment A is non-inferior to treatment B.  In this trial, we have two 
groups of patients who are going to be randomly assigned treatments.  In addition, a response 
variable will be measured on each patient.  In order to judge the efficacy of each treatment, we 
are going to make the comparison, which can be called the treatment difference, between the 
mean of the response variable of the two groups of patients.  If the confidence interval of the 
treatment difference is on the right side of non-inferiority margin −𝑀2 (with 𝑀2 > 0), then we 
can say that treatment A is non-inferior to treatment B.  Otherwise, we cannot state that treatment 
A is non-inferior to treatment B. 
The definition of non-inferiority sounds simple.  However, there is a hazard associated 
with non-inferiority trials in that making conclusions in some non-inferiority trials is often 
complicated.  For example, suppose A, B, C are three different drugs.  Let us make some 
assumptions: 
1. Drug A is a proven drug for disease X. 
2. Drug B is non-inferior to drug A. 
3. Drug C is non-inferior to drug B. 
Then, we can make some conclusions.  According to the assumption 1 and 2, we can say 
that drug B is better than placebo.  However, we cannot make too strong of a claim by adding in 
assumption 3.  Although, drug C is non-inferior to drug B, we cannot be sure that drug C is better 
than the placebo.  Making things worse, we cannot conclude that drug C is non-inferior to drug 
A, either. 
We can note that selection of this margin is a big challenge and an active area of research.  
If the non-inferiority margin is too small, it will be difficult to demonstrate usefulness of the new 
drug, which may be able to treat some diseases.  On the other hand, if the non-inferiority margin 
5 
is too large, it may lead to the approval of some treatments, which have only slight or no benefit 
to patients.  In this report, we are focusing on the selection of a non-inferiority margin. 
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Figure 1.1.  Relationship between the superiority margin and confidence interval 
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Figure 1.2.  Relationship between the equivalence margin and confidence interval 
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Figure 1.3.  Relationship between the non-inferiority margin and confidence interval 
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Chapter 2 - Non-inferiority Trials Considerations 
 Assay Sensitivity 
“Assay sensitivity is a study property defined as the ability to distinguish an effective 
treatment from a less effective or ineffective treatment” (FDA, 2010). Assay sensitivity is 
therefore a very important issue in the research of non-inferiority trials, since the goal of non-
inferiority trial is to compare different treatments.  If a non-inferiority trial lacks assay 
sensitivity, then any statistical analysis of this trial will have no practical meaning. 
According to the FDA, evidence of assay sensitivity is demonstrated in two ways: 
1) Historical evidence of effectiveness of the active control.  In other words, we can 
easily distinguish the proved active control from placebo. 
2) Design of the proposed non-inferiority study. 
 Sample Size 
Sample size is another issue that needs to be considered in the study of non-inferiority 
trials.  Generally, the sample sizes of non-inferiority trials, active-controlled superiority trials, 
and placebo-controlled trials satisfy the following two relationships: 
1) The sample sizes of non-inferiority trials are smaller than the sample sizes of active-
controlled superiority trials. 
2) The sample sizes of placebo-controlled trials are smaller than the sample sizes of non-
inferiority trials (Snapinn, 2000). 
In addition, according to the FDA, the sample size of a non-inferiority trial is related to 
many factors, including the estimated success rate of both the active control and the new 
treatment, the margin of difference, and the variance.  If we do not change all of the factors 
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except for the margin of difference, we can see the following pattern: the sample size increases 
as the margin of difference decreases; the sample size decreases as the margin of difference 
increases.  
 Constancy Condition 
Constancy condition is an issue we need to consider when we are dealing with the non-
inferiority trials without placebo group.  Constancy condition means that we can hold the effect 
of the active control over time in non-inferiority trials (Chow & Shao, 2005).  In practice, even 
though we have the active control, the effect of the active control in the current patients might be 
not as good as the effect in the historical patients.  Without the placebo group, we are not able to 
test the effect of the active control.  As a result, lack constancy condition will result in a useless 
statistical analysis. 
 Selecting Margins 
 General Method 
In Chapter 1, we give the definition of non-inferior as phrased below below by 
Rothmann, et al(2012):  
 
“If the effect of an experimental therapy on an endpoint is either better than or not too 
much worse than the effect of a control therapy on that same endpoint, the experimental 
therapy’s effect is said to be non-inferior to the effect of the control therapy.  It is 
common to say that the experimental therapy is non-inferior to the control therapy.” 
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It is clear that we need to explicitly define how much is ‘not too much’ if we want to analyze 
non-inferiority trials.  In other words, we need to know how to estimate the non-inferiority 
margin. 
First, let us make some assumptions. 
𝑦𝐴𝑖 : Response for active control agent for 𝑖
𝑡ℎ subject, 
𝑦𝐴𝑖~𝑁(𝜇𝐴, 𝜎𝐴
2), 𝑖 = 1, 2,⋯ , 𝑛𝐴 , 
𝑦𝑇𝑖 : Response for test therapy for 𝑖
𝑡ℎ subject, 
𝑦𝑇𝑖~𝑁(𝜇𝑇 , 𝜎𝑇
2), 𝑖 = 1, 2,⋯ , 𝑛𝑇 , 
𝑦𝑃𝑖 : Response for placebo for 𝑖
𝑡ℎ subject, 
𝑦𝑃𝑖~𝑁(𝜇𝑃, 𝜎𝑃
2), 𝑖 = 1, 2,⋯ , 𝑛𝑃 , 
𝑀1: Superiority margin (𝑀1 > 0), and 
−𝑀2: Non-inferiority margin (𝑀2 > 0). 
The hypotheses for non-inferiority trial: 
𝐻0: 𝜇𝑇 − 𝜇𝐴 ≤ −𝑀2 
𝐻1: 𝜇𝑇 − 𝜇𝐴 > −𝑀2 
According to the International Conference on Harmonization Guideline E10 (ICH, 2001), 
the non-inferiority margin −𝑀2 should be chosen to satisfy at least the following two criteria: 
Criterion 1:     We want the ability to claim that the test therapy is non-inferior to the active 
control agent and is superior to the placebo (even though the placebo is not 
considered in the active control trial). 
Criterion 2:      The non-inferiority margin should be suitably conservative and variability should 
be taken into account. 
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If −𝑀2 is a fixed number, then we are able to test the hypotheses by using some classic 
statistical techniques.  Unfortunately, in reality, usually, −𝑀2  is not pre-specified (Chow & 
Shao, 2005). 
In addition, it is almost impossible to find a fixed −𝑀2 under criterion 1.  Let 𝑀1 > 0 be 
a superiority margin associated with a placebo-controlled trial, which is a superiority trial that 
examines a test therapy over a placebo control.  We are able to assume that 𝜇𝐴 − 𝜇𝑃 > 𝑀1 , 
because the historical evidence has proved that the active control is superior to the placebo. 
However, when the test therapy is non-inferior to the active control, for a fixed 𝑀2, we 
are not able to say that the test therapy in superior to the placebo unless 𝑀2 = 0.  Statistically 
speaking, if 𝜇𝐴 − 𝜇𝑃 > 𝑀1 and 𝜇𝑇 − 𝜇𝐴 > −𝑀2, then  
𝜇𝑇 − 𝜇𝑃 = 𝜇𝑇 − 𝜇𝐴 + 𝜇𝐴 − 𝜇𝑃 > 𝑀1 −𝑀2 
So, we cannot make statement that 𝜇𝑇 − 𝜇𝑃 > 𝑀1 unless 𝑀2 = 0. Also, if 𝜇𝑇 − 𝜇𝑃 > 0, then we 
can assume that 𝜇𝑇 − 𝜇𝑃 > 𝑀1 −𝑀2 > 0. Therefore, 𝑀1 > 𝑀2.  In addition, we have 𝜇𝐴 − 𝜇𝑃 >
𝑀1 > 𝑀2. We can assume the following equation based on the above result:  𝑀2 = 𝛾(𝜇𝐴 − 𝜇𝑃) 
where 0 ≤ 𝛾 ≤ 1.  In addition, 𝛾 is a fix number.  Therefore, the non-inferiority margin 𝑀2 is 
associated with the active control effect 𝜇𝐴 − 𝜇𝑃. 
Next, we are going to determine a non-inferiority margin under criterion 1.  Let 𝑀1 > 0 
be a superiority margin associated with a placebo control submitted to the trial.  Since we have 
𝜇𝐴 − 𝜇𝑃 > 𝑀1 > 𝑀2 , then we can assume that 𝑀2  and the superiority margin 𝑀1  have the 
following relationship:  𝑀2 = 𝑟𝑀1 where 𝑟 is a pre-specified number, which is between 0 and 1.  
Suppose that the test therapy is non-inferior to the active control agent and superior to the 
placebo, then we have the following set of inequalities: 
{
𝜇𝑇 − 𝜇𝐴 > −𝑀2
𝜇𝑇 − 𝜇𝑃 > 𝑀1
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If 𝜇𝑇 − 𝜇𝐴 reaches the lowest value −𝑀2, then we have 𝜇𝑇 = 𝜇𝐴 −𝑀2.Thus,  
𝜇𝑇 − 𝜇𝑃 = 𝜇𝐴 −𝑀2 − 𝜇𝑃 > 𝑀1 
so that 𝜇𝐴 − 𝜇𝑃 −𝑀1 > 𝑀2. In this case, if 𝑀2 reaches the highest value, then  
𝑀2 = 𝜇𝐴 − 𝜇𝑃 −𝑀1. 
Therefore, we have 
{
𝑀2 = 𝜇𝐴 − 𝜇𝑃 −𝑀1
𝑀1 =
𝑀2
𝑟
⟹ 𝑀2 = 𝜇𝐴 − 𝜇𝑃 −
𝑀2
𝑟
 
⇒ 𝑟𝑀2 = 𝑟(𝜇𝐴 − 𝜇𝑃) − 𝑀2 
⇒ (1 + 𝑟)𝑀2 = 𝑟(𝜇𝐴 − 𝜇𝑃) 
   ⇒ 𝑀2 =
𝑟
1+𝑟
(𝜇𝐴 − 𝜇𝑃). 
Since we assume 𝑀2 = 𝛾(𝜇𝐴 − 𝜇𝑃), then we have 𝛾 =
𝑟
1+𝑟
.  As we know, 𝑟 ≤ 1, then 
1 − 𝛾 =
1
1 + 𝑟
⇒
1
1 − 𝛾
= 1 + 𝑟 ⇒
𝛾
1 − 𝛾
= 𝑟 ≤ 1 ⇒ 𝛾 ≤ 1 − 𝛾 ⇒ 2𝛾 ≤ 1 ⇒ 𝛾 ≤
1
2
 
In addition, we need to take variability into account. Suppose that we have the same assumption 
in the beginning of this section. 
𝑦𝐴𝑖 : Response for active control agent for 𝑖
𝑡ℎ subject, 
𝑦𝐴𝑖~𝑁(𝜇𝐴, 𝜎𝐴
2), 𝑖 = 1, 2,⋯ , 𝑛𝐴 , 
𝑦𝑇𝑖 : Response for test therapy for 𝑖
𝑡ℎ subject, 
𝑦𝑇𝑖~𝑁(𝜇𝑇 , 𝜎𝑇
2), 𝑖 = 1, 2,⋯ , 𝑛𝑇 , 
𝑦𝑃𝑖 : Response for placebo for 𝑖
𝑡ℎ subject, 
𝑦𝑃𝑖~𝑁(𝜇𝑃, 𝜎𝑃
2), 𝑖 = 1, 2,⋯ , 𝑛𝑃 , 
Then  
𝑦𝑇∙̅̅ ̅̅ =
1
𝑛𝑇
∑ 𝑦𝑇𝑖
𝑛𝑇
1  ,  
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𝑦𝑃∙̅̅ ̅̅ =
1
𝑛𝑃
∑ 𝑦𝑃𝑖
𝑛𝑃
1 .,  
𝐸(𝑦𝑇∙̅̅ ̅̅ − 𝑌𝑃∙̅̅̅̅ ) = 𝜇𝑇 − 𝜇𝑃, and 
𝑉𝐴𝑅𝑇−𝑃(𝑦𝑇∙̅̅ ̅̅ − 𝑌𝑃∙̅̅̅̅ ) =
𝜎𝑇
2
𝑛𝑇
+
𝜎𝑃
2
𝑛𝑃
 , 
So that 
𝜇?̂?~𝑁 (𝜇𝑇 ,
𝜎𝑇
2
𝑛𝑇
)  and  𝜇?̂?~𝑁 (𝜇𝑃,
𝜎𝑃
2
𝑛𝑃
). 
Using independence, we have (𝜇?̂? − 𝜇?̂?)~𝑁 (𝜇𝑇 − 𝜇𝑝,
𝜎𝑇
2
𝑛𝑇
+
𝜎𝑃
2
𝑛𝑃
) . When 𝜇𝑇 = 𝜇𝐴 −𝑀2 , 
according to the properties of standard normal distribution, 
𝑃(𝜇?̂? − 𝜇?̂? < 𝑀1) = 𝑃
(
 
 
𝑍 <
𝑀1−(𝜇𝑇−𝜇𝑝)
√
𝜎𝑇
2
𝑛𝑇
+
𝜎𝑃
2
𝑛𝑃
)
 
 
 = 𝑃
(
 
 
𝑍 <
𝑀1−𝜇𝐴+𝑀2+𝜇𝑝
√
𝜎𝑇
2
𝑛𝑇
+
𝜎𝑃
2
𝑛𝑃
)
 
 
  
 = 𝑃 (𝑍 <
𝑀1+𝑀2−(𝜇𝐴−𝜇𝑝)
𝑆𝐸𝑇−𝑃
).  
We also have 𝑀2 =
𝑟
1+𝑟
(𝜇𝐴 − 𝜇𝑝).  Therefore, 
𝑀1 +𝑀2 − (𝜇𝐴 − 𝜇𝑝) = 𝑀1 +
𝑟
1+𝑟
(𝜇𝐴 − 𝜇𝑝) − (𝜇𝐴 − 𝜇𝑝)  
 = 𝑀1 +
𝑟
1+𝑟
(𝜇𝐴 − 𝜇𝑝) −
1+𝑟
1+𝑟
(𝜇𝐴 − 𝜇𝑝)  
 = 𝑀1 −
1
1+𝑟
(𝜇𝐴 − 𝜇𝑝) . 
In addition, 𝑀1 =
𝑀2
𝑟
  and 𝑀2 =
𝑟
1+𝑟
(𝜇𝐴 − 𝜇𝑝), so that 
𝑀1 −
1
1+𝑟
(𝜇𝐴 − 𝜇𝑝) =
𝑀2
𝑟
−
1
1+𝑟
(𝜇𝐴 − 𝜇𝑝) =
1
1+𝑟
(𝜇𝐴 − 𝜇𝑝) −
1
1+𝑟
(𝜇𝐴 − 𝜇𝑝) = 0. 
As a result, 𝑀1 +𝑀2 − (𝜇𝐴 − 𝜇𝑝) = 0.  When 𝜇𝑇 = 𝜇𝑃 −𝑀2, according to the definition of 
standard normal distribution, 
𝑃(𝜇?̂? − 𝜇?̂? < 𝑀1) ≤ 𝑃 (𝑍 <
𝑀1+𝑀2−(𝜇𝐴−𝜇𝑝)
𝑆𝐸𝑇−𝑃
) ≤ 𝑃(𝑍 < 0) =
1
2
 . 
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Now, we have: 
𝑃(𝜇?̂? − 𝜇?̂? < 𝑀1) ≤ 𝑃 (𝑍 <
𝑀1+𝑀2−(𝜇𝐴−𝜇𝑝)
𝑆𝐸𝑇−𝑃
) ≤ 𝑃(𝑍 < 0) =
1
2
  
⇒
𝑀1+𝑀2−(𝜇𝐴−𝜇𝑝)
𝑆𝐸𝑇−𝑃
= −𝑍1−𝜀 (assume the Z value) 
⇒ 𝑀1 +𝑀2 − (𝜇𝐴 − 𝜇𝑝) = (−𝑍1−𝜀)𝑆𝐸𝑇−𝑃  
⇒ 𝑀2 = (𝜇𝐴 − 𝜇𝑝) − 𝑀1 − 𝑍1−𝜀𝑆𝐸𝑇−𝑃  
Again, using the equation 𝑀1 =
𝑀2
𝑟
. 
𝑀2 = (𝜇𝐴 − 𝜇𝑝) − 𝑀1 − 𝑍1−𝜀𝑆𝐸𝑇−𝑃  
⇒ 𝑀2 = (𝜇𝐴 − 𝜇𝑝) −
𝑀2
𝑟
− 𝑍1−𝜀𝑆𝐸𝑇−𝑃  
⇒
𝑟+1
𝑟
𝑀2 = (𝜇𝐴 − 𝜇𝑝) − 𝑍1−𝜀𝑆𝐸𝑇−𝑃  
⇒ 𝑀2 =
𝑟
𝑟+1
[(𝜇𝐴 − 𝜇𝑝) − 𝑍1−𝜀𝑆𝐸𝑇−𝑃]  
In conclusion, the non-inferiority margin 𝑀2 =
𝑟
𝑟+1
[(𝜇𝐴 − 𝜇𝑝) − 𝑍1−𝜀𝑆𝐸𝑇−𝑃]. Finally,  
𝐻0: 𝜇𝑇 − 𝜇𝑃 ≤ 𝑀1 
𝐻1: 𝜇𝑇 − 𝜇𝑃 > 𝑀1. 
Suppose the type II power 1 − β is the probability correctly rejecting the null hypothesis 
when the null hypothesis is not true, then the power of the test is approximately equal to 
Φ(
𝜇𝑇−𝜇𝑃−𝑀1
𝑆𝐸𝑇−𝑃
− 𝑍1−𝛼). 
Suppose  𝜇𝑇 = 𝜇𝐴 −𝑀2, then  
𝜇𝐴−𝜇𝑃−𝑀1−𝑀2
𝑆𝐸𝑇−𝑃
− 𝑍1−𝛼 = 𝑍𝛽 (Chow & Shao, 2005). Therefore, 
𝑀2 +𝑀1 = (𝜇𝐴 − 𝜇𝑝) − (𝑍1−𝛼 + 𝑍𝛽)𝑆𝐸𝑇−𝑃. 
Also, 𝑀1 =
𝑀2
𝑟
, then  
𝑀2 +
𝑀2
𝑟
= (𝜇𝐴 − 𝜇𝑝) − (𝑍1−𝛼 + 𝑍𝛽)𝑆𝐸𝑇−𝑃 , then 
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𝑀2
𝑟+1
𝑟
= (𝜇𝐴 − 𝜇𝑝) − (𝑍1−𝛼 + 𝑍𝛽)𝑆𝐸𝑇−𝑃 , then 
𝑀2 =
𝑟
1+𝑟
[(𝜇𝐴 − 𝜇𝑝) − (𝑍1−𝛼 + 𝑍𝛽)𝑆𝐸𝑇−𝑃]. 
Comparing this form to the non-inferiority margin we derived, we can see that 
𝑍1−𝜀 = 𝑍1−𝛼 + 𝑍𝛽. 
 Selecting Margin without Historical Data 
Although a clinical trial with test therapy, active control, and placebo is usually 
recommended for a non-inferiority trial (called a three-arm trial), it is very common that 
researchers have to conduct a clinical trial without placebo when use of the placebo is unethical.  
It is also highly possible that the trial does not have access to historical data since it does not 
have placebo group.  In general situations, we can estimate the non-inferiority margin −𝑀2 
based on the value of the superiority margin 𝑀1 as FDA recommends.  However, that process 
does not work anymore, since the superiority margin 𝑀1 depends on historical data.  Here, Chow 
and Shao (2005) provide an alternative solution to estimate non-inferiority margin. 
In this case, we usually know that the active control agent is the proven treatment.  In 
other words, the active control agent is ‘better’ than the placebo.  Applying the concept from 
Chapter 1, we know that active control agent is superior to placebo.  Therefore, we can assume 
that the power of the level 𝛼 test showing that the active control agent is superior to placebo by 
the margin 𝑀1is at the level 𝜂: 
𝑀2 = (𝑍1−𝛼 + 𝑍𝜂)𝑆𝐸𝐴−𝑃 − 𝑍1−𝜀𝑆𝐸𝑇−𝑃. 
In order to specify the non-inferiority margin, we are required to get some statistical information 
of the placebo group, such as the population variances.   
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𝑀2 = (𝑍1−𝛼 + 𝑍𝜂)√
𝜎𝐴2
𝑛𝐴
+ 𝑐2 − 𝑍1−𝜀√
𝜎𝑇2
𝑛𝑇
+ 𝑐2 
We replace c to the smaller estimated value of 
𝜎𝑇
√𝑛𝑇
 and 
𝜎𝐴
√𝑛𝐴
 (Chow & Shao, 2005). Since 
𝑆𝐸𝐴−𝑃 = √
𝜎𝐴2
𝑛𝐴
+
𝜎𝑃2
𝑛𝑃
  and  𝑆𝐸𝑇−𝑃 = √
𝜎𝑇2
𝑛𝑇
+
𝜎𝑃2
𝑛𝑃
, we use 𝑐2 to take place of  
𝜎𝑃
2
𝑛𝑃
.  Suppose we 
have a three arm non-inferiority trial.  One group takes new treatment.  One group takes proven 
treatment.  One group takes placebo.  According to the definition of placebo, 
𝜎𝑃
2
𝑛𝑃
 should be very 
small but not equal to 0.  Therefore, it is logical to use the smaller estimated value of 
𝜎𝑇
√𝑛𝑇
 and 
𝜎𝐴
√𝑛𝐴
 
to replace 
𝜎𝑃
√𝑛𝑃
. 
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Chapter 3 - A Case Study 
 Statistical Analysis 
In this chapter, we estimate a two-arm non-inferiority margin for a trial, which is related 
to a blood pressure study.  The data, from Wellek (2010) is provided in Table 3.1.  The 
calculation in this chapter is processed in SAS.  The SAS code and output are provided in 
Appendix A.  This clinical trial only has two treatments: moxonidin and captopril.  Moxonidin is 
a proven treatment for blood pressure.  In contrast, captopril is a new treatment.  In this trial, 
researchers measure the reduction of blood pressure (mm Hg) after 4 weeks of treatment.  A 
group of patients takes 0.2 to 0.4 mg moxonidin every day during the treatment period.  The 
other patients take 25 to 50 mg captopril daily over the treatment period.  Assume that we do not 
have historical data for estimating the non-inferiority margin.  Also, we know that it is a two-arm 
non-inferiority trial with active control (moxonidin) and therapy test (captopril).   
To estimate the non-inferiority margin, we can use the following result from Chapter 2: 
𝑀2 = (𝑍1−𝛼 + 𝑍𝜂)√
𝜎𝐴2
𝑛𝐴
+ 𝑐2 − 𝑍1−𝜀√
𝜎𝑇2
𝑛𝑇
+ 𝑐2 
where c is the smaller estimated value of  
𝜎𝑇
√𝑛𝑇
  and  
𝜎𝐴
√𝑛𝐴
 . Before we calculate the non-inferiority 
margin, we need to test if the data fit the assumption of non-inferiority trials.  It is clear that the 
sample size is very small in this case (Table 3.1) and hence, may be an issue for this study. 
Looking at the results from SAS output, we can know some basic statistics of the data set.  
The sample sizes of both group is 12.  In the moxonidin group, the mean is 4.175, the variance is 
49.704, and the standard deviation is 7.050 (Table 3.2).  In the captopril group, the mean is 
7.208, the variance is 43.886, and the standard deviation is 6.625 (Table 3.3). 
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In addition, we need to test the normality of the data.  For the moxonidin group, the data 
does not fail the normality test, since the Shapiro-Wilk statistic is 0.916 with the p-value = 0.254 
(Table 3.4).  Similarly, the captopril group does not fails the normality test, since the Shapiro-
Wilk statistic is 0.933 with p-value = 0.413 (Table 3.5).  Also, if we look at the QQ plots 
(Figures 3.1 and 3.2), we can conclude that the data fits the assumption of normality. 
In order to find the estimated non-inferiority margin, we need to give values for 𝜀, 𝛼, 𝜂.  
Let 𝛼 = 0.05 and 𝜂 = 0.80, we get five different estimated margins based on five different 
values of 𝜀 in Table 3.6.  It is clear that the value of the estimated margin drops as the value of 𝜀 
decreases.  In this case study, first, we can use c, which is the smaller estimated value of 
𝜎𝑇
√𝑛𝑇
  and 
𝜎𝐴
√𝑛𝐴
  to test whether captopril is non-inferior to moxonidin. 
According to the result from the R program, the 90% confidence interval of the 
difference between moxonidin group and captopril group is (−1.763, 7.830).  We can see that 
−1.763, which is the lower bound of the 90% CI, is greater than any of the estimated non-
inferiority margins −𝑀2 .  As a result, we can conclude that captopril is non-inferior to 
moxonidin. 
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 Tables and Figures 
 
Table 3.1.  Reduction of Blood Pressure in Moxonidin Group and Captopril Group 
Moxonidin Captopril 
𝑖 𝑋𝑖 𝑗 𝑌𝑗 
1 10.3 1 3.3 
2 11.3 2 17.7 
3 2.0 3 6.7 
4 -6.1 4 11.1 
5 6.2 5 -5.8 
6 6.8 6 6.9 
7 3.7 7 5.8 
8 -3.3 8 3.0 
9 -3.6 9 6.0 
10 -3.5 10 3.5 
11 13.7 11 18.7 
12 12.6 12 9.6 
 
Table 3.2.  Basic Statistical Measures of Moxonidin 
Basic Statistical Measures 
Location Variability 
Mean 4.175 Std Deviation 7.050 
Median 4.950 Variance 49.704 
Mode . Range 19.800 
  Interquartile Rang 14.200 
 
Table 3.3.  Basic Statistical Measures of Captopril 
Basic Statistical Measures 
Location Variability 
Mean 7.208 Std Deviation 6.625 
Media 6.350 Variance 43.886 
Mode . Range 24.500 
  Interquartile Range 6.950 
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Table 3.4.  Test for Normality of Moxonidin 
Tests for Normality 
Test Statistic P Value 
Shapiro-Wilk W 0.916 Pr<W 0.254 
Kolmogorov-Smirnov D 0.189 Pr>D >0.150 
Cramer-von Mises W-Sq 0.551 Pr>W-Sq >0.250 
Anderson-Darling A-Sq 0.396 Pr>A-Sq >0.250 
 
 
Table 3.5.  Test for Normality of Captopril 
Test for Normality 
Test Statistic P Value 
Shapiro-Wilk W 0.934 Pr<W 0.413 
Kolmogorov-Smirnov D 0.185 Pr>D >0.150 
Cramer-von Mises W-Sq 0.074 Pr>W-Sq 0.235 
Anderson-Darling A-Sq 0.443 Pr>A-Sq 0.242 
 
 
Table 3.6.  Estimated Non-inferiority Margin When α=0.05 and β=0.8 
𝜀 0.25 0.20 0.15 0.10 0.05 
−𝑀2 -5.120 -4.668 -4.141 -3.478 -2.495 
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Figure 3.1.  Q-Q Plot for Moxonidin 
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Figure 3.2.  Q-Q Plot for Captopril 
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Chapter 4 - Summary 
In this report, we introduced the general idea of non-inferiority trials.  There is evidence 
indicating that non-inferiority trails are becoming popular in the field of clinical research.  We 
also know that non-inferiority trials are different from the other two major types of clinical trials, 
namely superiority and equivalence trials.  It is clear that non-inferiority trials can reduce risk to 
patients because the patients none have to receive a placebo treatment. 
However, there are several challenges in the study of non-inferiority trials.  We must take 
into consideration assay sensitivity, sample size, constancy condition, and non-inferiority 
margin, although the major focus of this report is the non-inferiority margin.  We provided the 
formula for specifying a non-inferiority margin by using the guideline recommended by the 
International Conference on Harmonization. 
In the end, we used a case study related to blood pressure to implement the theoretical 
results for selecting the margin of a non-inferiority trial.  The results showed that captopril is 
non-inferior to moxonidin.  We also note that, while not included in the actual trial, the standard 
deviation of the placebo group plays a very important role in specifying the hypotheses of a non-
inferiority trial. 
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Appendix A – Case Study 
 SAS and R Code for Case Study 
data moxonidin; 
input moxonidin; 
cards; 
10.3 
11.3 
2.0 
-6.1 
6.2 
6.8 
3.7 
-3.3 
-3.6 
-3.5 
13.7 
12.6 
; 
 
data captopril; 
input captopril; 
cards; 
3.3 
17.7 
6.7 
11.1 
-5.8 
6.9 
5.8 
3.0 
6.0 
3.5 
18.7 
9.6 
; 
 
proc univariate data=moxonidin normal; 
qqplot moxonidin / normal(mu=est sigma=est color=red l=1); 
run; 
 
proc univariate data=captopril normal; 
qqplot captopril / normal(mu=est sigma=est color=red l=1); 
run; 
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proc iml; 
moxonidin={10.3,11.3,2.0,-6.1,6.2,6.8,3.7,-3.3,-3.6,-3.5,13.7,12.6}; 
captopril={3.3,17.7,6.7,11.1,-5.8,6.9,5.8,3.0,6.0,3.5,18.7,9.6}; 
moxonidin_u=mean(moxonidin); 
captopril_u=mean(captopril); 
u=captopril_u-moxonidin_u; 
print u; 
moxonidin_var=var(moxonidin); 
captopril_var=var(captopril); 
c2=min(moxonidin_var/12,captopril_var/12); 
c=sqrt(c2); 
print c; 
margin1=(probit(1-0.05)+probit(0.8))*sqrt((moxonidin_var/12)+c2)-probit(1-
0.25)*sqrt((captopril_var/12)+c2); 
margin2=(probit(1-0.05)+probit(0.8))*sqrt((moxonidin_var/12)+c2)-probit(1-
0.2)*sqrt((captopril_var/12)+c2); 
margin3=(probit(1-0.05)+probit(0.8))*sqrt((moxonidin_var/12)+c2)-probit(1-
0.15)*sqrt((captopril_var/12)+c2); 
margin4=(probit(1-0.05)+probit(0.8))*sqrt((moxonidin_var/12)+c2)-probit(1-
0.1)*sqrt((captopril_var/12)+c2); 
margin5=(probit(1-0.05)+probit(0.8))*sqrt((moxonidin_var/12)+c2)-probit(1-
0.05)*sqrt((captopril_var/12)+c2); 
print margin1 margin2 margin3 margin4 margin5; 
w1=u+(probit(1-0.05)+probit(0.8))*sqrt((moxonidin_var/12)+c2)-probit(1-
0.25)*sqrt((captopril_var/12)+c2) 
-probit(1-0.05)*sqrt((moxonidin_var/12)+(captopril_var/12)); 
w2=u+(probit(1-0.05)+probit(0.8))*sqrt((moxonidin_var/12)+c2)-probit(1-
0.2)*sqrt((captopril_var/12)+c2) 
-probit(1-0.05)*sqrt((moxonidin_var/12)+(captopril_var/12)); 
w3=u+(probit(1-0.05)+probit(0.8))*sqrt((moxonidin_var/12)+c2)-probit(1-
0.15)*sqrt((captopril_var/12)+c2) 
-probit(1-0.05)*sqrt((moxonidin_var/12)+(captopril_var/12)); 
w4=u+(probit(1-0.05)+probit(0.8))*sqrt((moxonidin_var/12)+c2)-probit(1-
0.1)*sqrt((captopril_var/12)+c2) 
-probit(1-0.05)*sqrt((moxonidin_var/12)+(captopril_var/12)); 
w5=u+(probit(1-0.05)+probit(0.8))*sqrt((moxonidin_var/12)+c2)-probit(1-
0.05)*sqrt((captopril_var/12)+c2) 
-probit(1-0.05)*sqrt((moxonidin_var/12)+(captopril_var/12)); 
print w1 w2 w3 w4 w5; 
w6=u+(probit(1-0.05)+probit(0.8))*sqrt((moxonidin_var/12)+1*1)-probit(1-
0.05)*sqrt((captopril_var/12)+1*1) 
-probit(1-0.05)*sqrt((moxonidin_var/12)+(captopril_var/12)); 
w7=u+(probit(1-0.05)+probit(0.8))*sqrt((moxonidin_var/12)+2*2)-probit(1-
0.05)*sqrt((captopril_var/12)+2*2) 
-probit(1-0.05)*sqrt((moxonidin_var/12)+(captopril_var/12)); 
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w8=u+(probit(1-0.05)+probit(0.8))*sqrt((moxonidin_var/12)+3*3)-probit(1-
0.05)*sqrt((captopril_var/12)+3*3) 
-probit(1-0.05)*sqrt((moxonidin_var/12)+(captopril_var/12)); 
w9=u+(probit(1-0.05)+probit(0.8))*sqrt((moxonidin_var/12)+4*4)-probit(1-
0.05)*sqrt((captopril_var/12)+4*4) 
-probit(1-0.05)*sqrt((moxonidin_var/12)+(captopril_var/12)); 
w10=u+(probit(1-0.05)+probit(0.8))*sqrt((moxonidin_var/12)+5*5)-probit(1-
0.05)*sqrt((captopril_var/12)+5*5) 
-probit(1-0.05)*sqrt((moxonidin_var/12)+(captopril_var/12)); 
print w6 w7 w8 w9 w10; 
run; 
 
moxonidin<-c(10.3,11.3,2.0,-6.1,6.2,6.8,3.7,-3.3,-3.6,-3.5,13.7,12.6) 
captopril<-c(3.3,17.7,6.7,11.1,-5.8,6.9,5.8,3.0,6.0,3.5,18.7,9.6) 
t.test(captopril,moxonidin,conf.level=0.9) 
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 Tables 
 
Table A.1.  Moments of Moxonidin 
Moments 
N 12 Sum Weights 12 
Mean 4.175 Sum Observation 50.1 
Std Deviation 7.050 Variance 49.704 
Skewness -0.110 Kurtosis -1.563 
Uncorrected SS 755.91 Corrected SS 546.743 
Coeff Variation 168.8646 Std Error Mean 2.035 
 
 
Table A.2.  Test for Location of Moxonidin 
Tests for Location: Mu0=0 
Test Statistic P Value 
Student’s t t 2.051 Pr>|t| 0.065 
Sign M 2 Pr>=|M| 0.388 
Singed Rank S 24 Pr>=|S| 0.064 
 
 
Table A.3.  Quantiles of Moxonidin 
Quantiles (Definition 5) 
Quantile Estimate 
100% Max 13.70 
99% 13.70 
95% 13.70 
90% 12.60 
75% Q3 10.80 
50% Median 4.95 
25% Q1 -3.40 
10% -3.60 
5% -6.10 
1% -6.10 
0% Min -6.10 
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Table A.4.  Extreme Observations of Moxonidin 
Extreme Observations 
Lowest Highest 
Value Ob Value Ob 
-6.1 4 6.8 6 
-3.6 9 10.3 1 
-3.5 10 11.3 2 
-3.3 8 12.6 12 
2.0 3 13.7 11 
 
 
Table A.5.  Moments of Captopril 
Moments 
N 12 Sum Weights 12 
Mean 7.208 Sum Observations 86.5 
Std Deviation 6.625 Variance 43.886 
Skewness 0.133 Kurtosis 0.810 
Uncorrected SS 1106.27 Corrected SS 482.749 
Coeff Variation 91.903 Std Error Mean 1.912 
 
 
Table A.6.  Tests for Loation of Captopril 
Tests for Location: Mu0=0 
Test Statistic P Value 
Student’s t t 3.769 Pr>|t| 0.003 
Sign M 5 Pr>=|M| 0.006 
Signed Rank S 34.5 Pr>=|S| 0.004 
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Table A.7.  Quantiles of Captopril 
Quantiles (Definition 5) 
Quantile Estimate 
100% Max 18.70 
99% 18.70 
95% 18.70 
90% 17.70 
75% Q3 10.35 
50% Median 6.35 
25% Q1 3.40 
10% 3.00 
5% -5.80 
1% -5.80 
0% Min -5.80 
 
Table A.8.  Extreme Observations of Captopril 
Extreme Observations 
Lowest Highest 
Value Obs Value Obs 
-5.8 5 6.9 6 
3.0 8 9.6 12 
3.3 1 11.1 4 
3.5 10 17.7 2 
5.8 7 18.7 11 
 
 
 
 
 
 
 
